Metraipolis › archive › dc_bdfe7d96a4dc

Randomised trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer: a study protocol of ARIADNE — Europe PMC PMID:40866060

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40866060
DOI
10.1136/bmjopen-2025-102626
License (as archived)
solo-consultazione
Archived
2026-11-10T08:15:13.238Z
SHA-256 of the archived text
b62164d9a7c20f2693341e77d265683b574d183772f3f92d24f3d973cc6d4afd
Stable URL of this page
https://metraipolis.com/documento/dc_bdfe7d96a4dc

How to cite

Randomised trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer: a study protocol of ARIADNE — Europe PMC PMID:40866060 — Europe PMC (en), https://europepmc.org/article/MED/40866060 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_bdfe7d96a4dc (Metraipolis archive dc_bdfe7d96a4dc, sha256 b62164d9a7c20f2693341e77d265683b574d183772f3f92d24f3d973cc6d4afd)
BibTeX
@misc{dcbdfe7d96a4dc,
  title = {Randomised trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer: a study protocol of ARIADNE — Europe PMC PMID:40866060},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40866060},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_bdfe7d96a4dc; sha256 b62164d9a7c20f2693341e77d265683b574d183772f3f92d24f3d973cc6d4afd},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40866060. Agents can read the archived copy with the MCP tool read_document.